18h
Pharmaceutical Technology on MSNAtsena’s ATSN-201 gains FDA fast track status for XLRS treatmentThe Phase I/II LIGHTHOUSE trial is assessing the safety and tolerability of the gene therapy in male subjects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results